ClinicalTrials.gg
CompletedNCT03828617Updated Nov 23, 2020Results posted

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

A Phase 3 interventional study of 20vPnC and 20vPnC in Pneumococcal Disease, sponsored by Pfizer. Completed at 21 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-23.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,710
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
3rd of 19
1,710 · median 668
Started
2019
with 1 other
Phase 3
14 of 19
1 open now
Registered
2nd of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 14 in phase 3, and was the 2nd registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

This is a Phase 3, randomized, double-blind study with a 4-arm parallel design. Adults 18 through 49 years of age with no history of pneumococcal vaccination will be randomized in a 2:2:2:1 ratio to receive a single dose of: 20vPnC Lot 1; 20vPnC Lot 2; 20vPnC Lot 3; or 13vPnC.

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adults ≥18 and \<50 years of age.
  2. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of product.
  3. Female subject of or male subject who is able to father children, and willing to use a highly effective method of as outlined in this protocol for at least 28 days after the dose of investigational product; or female subject not of childbearing potential or male subject not able to father children.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with any licensed or pneumococcal vaccine, or planned receipt through study participation.
  2. Serious chronic disorder including , severe (COPD) requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the subject from participating in the study.
  3. History of microbiologically proven invasive disease caused by S pneumoniae.
  4. Pregnant female subjects or breastfeeding female subjects (known or suspected).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,710 participants (actual)

Study arms

  • Experimental
    20vPnC Lot 1

    20vPnC Lot 1

    Biological: 20vPnC

  • Experimental
    20vPnC Lot 2

    20vPnC Lot 2

    Biological: 20vPnC

  • Experimental
    20vPnC Lot 3

    20vPnC Lot 3

    Biological: 20vPnC

  • Active comparator
    13vPnC

    13vPnC

    Biological: 13vPnC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 10 Days After Vaccination

    Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

    Time frame: Within 10 days after vaccination

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination

    Systemic events fever, fatigue, headache, muscle pain, joint pain were recorded by using an electronic diary. Fever was defined as greater than or equal to (\>=) 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity). Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

    Time frame: Within 7 days after vaccination

  3. Percentage of Participants With Any Adverse Events (AEs) Within 1 Month After Vaccination

    An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship. Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

    Time frame: Within 1 month after vaccination

  4. Percentage of Participants With Any Serious Adverse Events (SAEs) Within 6 Months After Vaccination

    An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event. Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

    Time frame: Within 6 month after vaccination

  5. Percentage of Participants With Any Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination

    An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

    Time frame: Within 6 months after vaccination

  6. Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Vaccination

    OPA titers were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA GMTs and 2-sided 95% CIs were calculated. Data for this outcome measure were planned to be analyzed for the 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) only.

    Time frame: 1 month after vaccination

Secondary outcomes

  1. Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Before Vaccination to 1 Month After Vaccination

    Fold rises are the ratios of the 1 month after vaccination to before vaccination OPA titers. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. Data for this outcome measure was planned to be analyzed for the 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) only.

    Time frame: Before vaccination to 1 month after vaccination

  2. Percentage of Participants With Greater Than or Equal to (>=) 4 -Fold Rise in Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Titers From Before Vaccination to 1 Month After Vaccination

    Percentage of participants with a \>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. Data for this outcome measure was planned to be analyzed for the 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) only.

    Time frame: Before vaccination to 1 month after vaccination

  3. Percentage of Participants With Serotype-specific Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to Lower Limit of Quantitation (>= LLOQ) at 1 Month After Vaccination

    The percentage of participants with OPA titers \>=LLOQ were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Data for this outcome measure was planned to be analyzed for the 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) only.

    Time frame: 1 month after vaccination

07

Results

Posted Nov 4, 2020

Participant flow

Participant flow — Overall Study
Milestone20vPnC Lot 120vPnC Lot 220vPnC Lot 313vPnC
Started489490486245
Vaccinated488489486245
Safety population488489486245
Evaluable immunogenicity population(eip)463473456232
Completed465475460235
Not completed24152610
Withdrew: Lost to follow-up2212237
Withdrew: No longer met eligibility criteria0113
Withdrew: Protocol violation0200
Withdrew: Withdrawal by subject2020

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 10 Days After Vaccination

Local reactions were recorded using an electronic diary. Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity). Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

Time frame:
Within 10 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Local Reactions Within 10 Days After Vaccination
percentage of participantsPooled 20vPnC13vPnC
Redness: Any7.0 (5.7 to 8.4)6.2 (3.5 to 10.0)
Redness: Mild3.9 (3.0 to 5.0)3.3 (1.4 to 6.4)
Redness: Moderate2.6 (1.9 to 3.6)2.9 (1.2 to 5.8)
Redness: Severe0.5 (0.2 to 1.0)0 (0.0 to 1.5)
Swelling: Any8.5 (7.1 to 10.1)8.6 (5.4 to 12.9)
Swelling: Mild5.4 (4.3 to 6.7)5.3 (2.9 to 9.0)
Swelling: Moderate2.9 (2.1 to 3.9)3.3 (1.4 to 6.4)
Swelling: Severe0.2 (0.0 to 0.6)0 (0.0 to 1.5)
Pain at the injection site: Any78.7 (76.5 to 80.8)75.7 (69.8 to 81.0)
Pain at the injection site: Mild50.0 (47.4 to 52.6)46.5 (40.1 to 53.0)
Pain at the injection site: Moderate27.5 (25.3 to 29.9)27.6 (22.1 to 33.6)
Pain at the injection site: Severe1.2 (0.7 to 1.9)1.6 (0.5 to 4.2)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination

Systemic events fever, fatigue, headache, muscle pain, joint pain were recorded by using an electronic diary. Fever was defined as greater than or equal to (\>=) 38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity). Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

Time frame:
Within 7 days after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
percentage of participantsPooled 20vPnC13vPnC
Fever: >=38.0 degree C (Any)1.2 (0.7 to 1.9)0.8 (0.1 to 2.9)
Fever: >=38.0 degree C to 38.4 degree C0.8 (0.4 to 1.3)0.4 (0.0 to 2.3)
Fever: >38.4 degree C to 38.9 degree C0.3 (0.1 to 0.7)0.4 (0.0 to 2.3)
Fever: >38.9 degree C to 40.0 degree C0.2 (0.0 to 0.6)0 (0.0 to 1.5)
Fever: >40.0 degree C0 (0.0 to 0.3)0 (0.0 to 1.5)
Fatigue: Any47.6 (45.0 to 50.2)43.6 (37.3 to 50.1)
Fatigue: Mild24.7 (22.5 to 27.0)24.3 (19.0 to 30.2)
Fatigue: Moderate21.2 (19.1 to 23.4)17.7 (13.1 to 23.1)
Fatigue: Severe1.7 (1.1 to 2.5)1.6 (0.5 to 4.2)
Headache: Any36.2 (33.7 to 38.7)37.9 (31.7 to 44.3)
Headache: Mild22.6 (20.5 to 24.8)27.2 (21.7 to 33.2)
Headache: Moderate12.0 (10.4 to 13.8)9.9 (6.4 to 14.3)
Headache: Severe1.6 (1.0 to 2.4)0.8 (0.1 to 2.9)
Muscle pain: Any62.1 (59.5 to 64.6)60.5 (54.0 to 66.7)
Muscle pain: Mild38.5 (36.0 to 41.0)38.7 (32.5 to 45.1)
Muscle pain: Moderate22.5 (20.4 to 24.8)19.8 (14.9 to 25.3)
Muscle pain: Severe1.1 (0.6 to 1.8)2.1 (0.7 to 4.7)
Joint pain: Any16.8 (14.9 to 18.8)14.0 (9.9 to 19.0)
Joint pain: Mild10.0 (8.5 to 11.6)7.8 (4.8 to 11.9)
Joint pain: Moderate6.5 (5.2 to 7.8)5.3 (2.9 to 9.0)
Joint pain: Severe0.4 (0.2 to 0.9)0.8 (0.1 to 2.9)
PrimaryPercentage of Participants With Any Adverse Events (AEs) Within 1 Month After Vaccination

An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship. Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

Time frame:
Within 1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Any Adverse Events (AEs) Within 1 Month After Vaccination
percentage of participantsPooled 20vPnC13vPnC
Percentage of Participants With Any Adverse Events (AEs) Within 1 Month After Vaccination6.8 (5.6 to 8.3)5.3 (2.9 to 8.9)
PrimaryPercentage of Participants With Any Serious Adverse Events (SAEs) Within 6 Months After Vaccination

An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event. Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

Time frame:
Within 6 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Any Serious Adverse Events (SAEs) Within 6 Months After Vaccination
percentage of participantsPooled 20vPnC13vPnC
Percentage of Participants With Any Serious Adverse Events (SAEs) Within 6 Months After Vaccination0.7 (0.3 to 1.3)0 (0.0 to 1.5)
PrimaryPercentage of Participants With Any Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination

An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. Data for this outcome measure was planned to be analyzed for the pooled 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) and 13vPnC group.

Time frame:
Within 6 months after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Any Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination
percentage of participantsPooled 20vPnC13vPnC
Percentage of Participants With Any Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination1.0 (0.6 to 1.7)2.0 (0.7 to 4.7)
PrimarySerotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Vaccination

OPA titers were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution. OPA GMTs and 2-sided 95% CIs were calculated. Data for this outcome measure were planned to be analyzed for the 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) only.

Time frame:
1 month after vaccination
Reported as:
Geometric mean · titer
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Vaccination
titer20vPnC Lot 120vPnC Lot 220vPnC Lot 3
Serotype 1199.5 (173.5 to 229.6)175.1 (152.5 to 201.0)164.6 (143.1 to 189.3)
Serotype 347.3 (42.7 to 52.4)46.8 (42.3 to 51.8)43.1 (38.9 to 47.8)
Serotype 41499.7 (1288.3 to 1745.6)1568.2 (1350.2 to 1821.4)1505.6 (1294.4 to 1751.3)
Serotype 5125.8 (108.6 to 145.7)135.6 (117.3 to 156.7)116.8 (100.9 to 135.2)
Serotype 6A4654.1 (4033.0 to 5371.0)3748.3 (3255.7 to 4315.4)3330.4 (2885.1 to 3844.6)
Serotype 6B4403.3 (3832.6 to 5059.0)4349.9 (3796.4 to 4984.1)3907.3 (3401.4 to 4488.3)
Serotype 7F1820.6 (1588.5 to 2086.5)1865.6 (1629.7 to 2135.7)1875.7 (1632.6 to 2154.9)
Serotype 9V5120.4 (4464.6 to 5872.7)4604.1 (4024.4 to 5267.5)4921.7 (4292.4 to 5643.2)
Serotype 142240.2 (1965.4 to 2553.5)2091.2 (1839.9 to 2376.8)2001.9 (1760.4 to 2276.5)
Serotype 18C3903.7 (3339.6 to 4563.2)4450.7 (3818.1 to 5188.0)4221.7 (3615.8 to 4929.2)
Serotype 19A1457.8 (1287.5 to 1650.6)1528.1 (1353.2 to 1725.6)1434.4 (1267.8 to 1623.0)
Serotype 19F524.5 (450.7 to 610.3)529.2 (455.6 to 614.6)549.0 (472.2 to 638.3)
Serotype 23F1416.1 (1182.4 to 1696.1)1547.5 (1294.9 to 1849.2)1434.6 (1197.8 to 1718.1)
Serotype 81595.0 (1402.7 to 1813.7)1345.9 (1185.9 to 1527.6)1624.3 (1430.4 to 1844.5)
Serotype 10A6328.1 (5407.7 to 7405.2)5692.6 (4890.2 to 6626.6)5962.2 (5121.3 to 6941.1)
Serotype 11A8656.2 (7308.4 to 10252.5)6728.5 (5693.2 to 7952.0)8720.3 (7408.6 to 10264.1)
Serotype 12F8563.0 (7321.5 to 10015.0)7907.5 (6764.8 to 9243.3)7412.4 (6331.8 to 8677.4)
Serotype 15B7342.8 (6108.1 to 8827.2)6356.9 (5325.0 to 7588.7)7018.9 (5853.8 to 8416.1)
Serotype 22F12507.5 (10318.3 to 15161.1)11213.4 (9337.1 to 13466.9)12728.6 (10571.7 to 15325.5)
Serotype 33F10745.7 (9042.0 to 12770.5)10328.2 (8737.0 to 12209.3)10418.2 (8815.3 to 12312.5)
Statistical analysis
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio (gmr): 1.14 · 95% CI 0.95 to 1.37
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio (gmr): 1.01 · 95% CI 0.88 to 1.16
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 0.96 · 95% CI 0.78 to 1.17
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 0.93 · 95% CI 0.77 to 1.12
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.24 · 95% CI 1.03 to 1.50
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.01 · 95% CI 0.85 to 1.21
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 0.98 · 95% CI 0.82 to 1.17
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.11 · 95% CI 0.93 to 1.33
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.07 · 95% CI 0.90 to 1.27
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 0.88 · 95% CI 0.72 to 1.07
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 0.95 · 95% CI 0.81 to 1.12
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 0.99 · 95% CI 0.81 to 1.21
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 0.92 · 95% CI 0.72 to 1.16
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.19 · 95% CI 1.00 to 1.40
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.11 · 95% CI 0.91 to 1.36
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.29 · 95% CI 1.03 to 1.60
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.08 · 95% CI 0.88 to 1.33
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.16 · 95% CI 0.91 to 1.46
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.12 · 95% CI 0.87 to 1.43
  • 20vPnC Lot 1 vs 20vPnC Lot 2 · Geometric mean ratio: 1.04 · 95% CI 0.83 to 1.30
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.21 · 95% CI 1.01 to 1.46
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.10 · 95% CI 0.96 to 1.26
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.00 · 95% CI 0.82 to 1.22
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.08 · 95% CI 0.89 to 1.31
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.40 · 95% CI 1.16 to 1.69
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.13 · 95% CI 0.94 to 1.35
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 0.97 · 95% CI 0.81 to 1.16
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.04 · 95% CI 0.87 to 1.25
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.12 · 95% CI 0.94 to 1.33
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 0.92 · 95% CI 0.75 to 1.13
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.02 · 95% CI 0.86 to 1.20
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 0.96 · 95% CI 0.78 to 1.17
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 0.99 · 95% CI 0.78 to 1.25
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 0.98 · 95% CI 0.83 to 1.16
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.06 · 95% CI 0.87 to 1.30
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 0.99 · 95% CI 0.80 to 1.24
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.16 · 95% CI 0.94 to 1.42
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.05 · 95% CI 0.82 to 1.33
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 0.98 · 95% CI 0.77 to 1.26
  • 20vPnC Lot 1 vs 20vPnC Lot 3 · Geometric mean ratio: 1.03 · 95% CI 0.82 to 1.29
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.06 · 95% CI 0.89 to 1.28
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.09 · 95% CI 0.95 to 1.24
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.04 · 95% CI 0.85 to 1.27
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.16 · 95% CI 0.96 to 1.41
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.13 · 95% CI 0.93 to 1.36
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.11 · 95% CI 0.93 to 1.33
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.99 · 95% CI 0.83 to 1.19
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.94 · 95% CI 0.78 to 1.12
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.04 · 95% CI 0.88 to 1.24
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.05 · 95% CI 0.86 to 1.29
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.07 · 95% CI 0.91 to 1.25
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.96 · 95% CI 0.79 to 1.17
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.08 · 95% CI 0.85 to 1.37
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.83 · 95% CI 0.70 to 0.98
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.95 · 95% CI 0.78 to 1.17
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.77 · 95% CI 0.62 to 0.96
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 1.07 · 95% CI 0.87 to 1.31
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.91 · 95% CI 0.71 to 1.15
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.88 · 95% CI 0.69 to 1.12
  • 20vPnC Lot 2 vs 20vPnC Lot 3 · Geometric mean ratio: 0.99 · 95% CI 0.79 to 1.24
SecondarySerotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Before Vaccination to 1 Month After Vaccination

Fold rises are the ratios of the 1 month after vaccination to before vaccination OPA titers. OPA GMFRs from before to 1 month after vaccination were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. Data for this outcome measure was planned to be analyzed for the 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) only.

Time frame:
Before vaccination to 1 month after vaccination
Reported as:
Geometric mean · fold rise
Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Before Vaccination to 1 Month After Vaccination
fold rise20vPnC Lot 120vPnC Lot 220vPnC Lot 3
Serotype 120.2 (17.6 to 23.1)17.8 (15.6 to 20.3)17.3 (15.0 to 19.8)
Serotype 35.0 (4.4 to 5.5)5.0 (4.5 to 5.5)4.6 (4.1 to 5.1)
Serotype 477.6 (63.8 to 94.4)94.7 (79.4 to 112.9)81.0 (67.0 to 97.8)
Serotype 58.7 (7.5 to 10.0)9.4 (8.2 to 10.7)8.0 (6.9 to 9.1)
Serotype 6A157.2 (132.6 to 186.3)119.6 (100.5 to 142.3)128.4 (107.6 to 153.1)
Serotype 6B72.5 (59.9 to 87.8)75.4 (62.9 to 90.4)70.5 (58.1 to 85.6)
Serotype 7F18.3 (15.5 to 21.7)19.5 (16.5 to 23.0)19.0 (16.1 to 22.5)
Serotype 9V25.4 (21.1 to 30.7)23.3 (19.4 to 27.9)21.6 (17.7 to 26.4)
Serotype 1418.2 (14.8 to 22.3)16.3 (13.2 to 20.0)18.1 (14.6 to 22.3)
Serotype 18C80.4 (63.9 to 101.2)95.0 (76.6 to 117.7)79.9 (63.8 to 100.0)
Serotype 19A35.9 (29.9 to 43.2)39.1 (32.4 to 47.1)41.8 (34.9 to 50.2)
Serotype 19F14.0 (12.0 to 16.5)14.7 (12.6 to 17.2)15.4 (13.1 to 18.0)
Serotype 23F99.5 (80.4 to 123.1)125.1 (102.4 to 152.7)120.9 (97.9 to 149.5)
Serotype 838.3 (31.3 to 46.8)38.8 (32.1 to 46.9)46.1 (37.9 to 56.0)
Serotype 10A20.8 (16.6 to 26.1)19.0 (15.2 to 23.7)20.2 (15.9 to 25.6)
Serotype 11A6.9 (5.4 to 8.9)5.0 (3.9 to 6.4)5.3 (4.2 to 6.7)
Serotype 12F175.5 (141.3 to 217.9)174.6 (140.8 to 216.7)175.7 (141.6 to 218.1)
Serotype 15B112.5 (83.8 to 150.9)84.2 (64.5 to 110.0)91.7 (69.4 to 121.3)
Serotype 22F83.8 (59.2 to 118.6)63.3 (46.8 to 85.7)77.8 (56.8 to 106.6)
Serotype 33F8.3 (6.7 to 10.4)8.6 (7.0 to 10.6)7.4 (6.0 to 9.1)
SecondaryPercentage of Participants With Greater Than or Equal to (>=) 4 -Fold Rise in Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Titers From Before Vaccination to 1 Month After Vaccination

Percentage of participants with a \>=4-fold rise in serotype-specific pneumococcal OPA titers from before vaccination to 1 month after vaccination along with corresponding 2-sided 95% CIs were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. Data for this outcome measure was planned to be analyzed for the 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) only.

Time frame:
Before vaccination to 1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Greater Than or Equal to (>=) 4 -Fold Rise in Serotype-specific Pneumococcal Opsonophagocytic Activity (OPA) Titers From Before Vaccination to 1 Month After Vaccination
percentage of participants20vPnC Lot 120vPnC Lot 220vPnC Lot 3
Serotype 183.7 (80.0 to 87.0)82.9 (79.2 to 86.2)82.4 (78.6 to 85.8)
Serotype 356.1 (51.4 to 60.8)57.8 (53.1 to 62.3)53.0 (48.3 to 57.7)
Serotype 485.0 (81.4 to 88.2)87.6 (84.1 to 90.5)86.2 (82.6 to 89.3)
Serotype 565.7 (61.2 to 70.1)67.2 (62.7 to 71.4)65.3 (60.7 to 69.7)
Serotype 6A94.5 (91.9 to 96.4)93.1 (90.4 to 95.3)93.0 (90.2 to 95.2)
Serotype 6B90.3 (87.1 to 93.0)91.4 (88.4 to 93.8)89.2 (85.8 to 91.9)
Serotype 7F76.8 (72.4 to 80.7)76.7 (72.3 to 80.6)80.0 (75.8 to 83.9)
Serotype 9V79.1 (74.8 to 83.0)79.5 (75.2 to 83.3)75.7 (71.1 to 79.9)
Serotype 1470.0 (65.4 to 74.3)67.7 (63.0 to 72.0)67.7 (63.1 to 72.1)
Serotype 18C83.0 (79.1 to 86.4)88.2 (84.8 to 91.0)84.5 (80.8 to 87.8)
Serotype 19A81.7 (77.8 to 85.2)81.8 (77.9 to 85.2)85.5 (81.8 to 88.6)
Serotype 19F74.0 (69.7 to 78.0)76.2 (72.0 to 80.0)75.2 (71.0 to 79.2)
Serotype 23F85.6 (82.0 to 88.7)88.2 (84.9 to 91.0)88.8 (85.5 to 91.5)
Serotype 882.0 (77.9 to 85.5)82.3 (78.3 to 85.8)82.5 (78.5 to 86.1)
Serotype 10A74.9 (70.0 to 79.3)74.5 (69.7 to 78.8)70.8 (65.9 to 75.4)
Serotype 11A52.4 (46.7 to 57.9)48.0 (42.4 to 53.6)42.2 (36.8 to 47.7)
Serotype 12F91.8 (88.6 to 94.3)93.1 (90.1 to 95.4)91.5 (88.2 to 94.1)
Serotype 15B81.6 (77.2 to 85.4)82.0 (77.9 to 85.7)81.0 (76.7 to 84.9)
Serotype 22F79.8 (75.0 to 84.1)82.1 (77.7 to 85.9)81.4 (76.8 to 85.4)
Serotype 33F62.7 (57.3 to 67.9)62.7 (57.5 to 67.8)62.7 (57.5 to 67.7)
SecondaryPercentage of Participants With Serotype-specific Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to Lower Limit of Quantitation (>= LLOQ) at 1 Month After Vaccination

The percentage of participants with OPA titers \>=LLOQ were calculated along with corresponding 2-sided 95% CIs for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Data for this outcome measure was planned to be analyzed for the 20vPnC vaccine groups (20vPnC Lots 1, 2 and 3) only.

Time frame:
1 month after vaccination
Reported as:
Number · percentage of participants
Percentage of Participants With Serotype-specific Opsonophagocytic Activity (OPA) Titers Greater Than or Equal to Lower Limit of Quantitation (>= LLOQ) at 1 Month After Vaccination
percentage of participants20vPnC Lot 120vPnC Lot 220vPnC Lot 3
Serotype 191.8 (88.9 to 94.1)92.8 (90.0 to 94.9)91.0 (87.9 to 93.4)
Serotype 389.7 (86.6 to 92.4)89.6 (86.4 to 92.2)88.9 (85.6 to 91.7)
Serotype 497.6 (95.7 to 98.8)97.0 (95.0 to 98.4)97.1 (95.1 to 98.5)
Serotype 580.3 (76.4 to 83.9)84.3 (80.7 to 87.5)81.3 (77.4 to 84.8)
Serotype 6A99.1 (97.8 to 99.8)98.1 (96.4 to 99.1)98.2 (96.5 to 99.2)
Serotype 6B97.6 (95.7 to 98.8)99.6 (98.5 to 99.9)98.9 (97.4 to 99.6)
Serotype 7F94.7 (92.2 to 96.6)94.0 (91.4 to 96.0)96.6 (94.5 to 98.1)
Serotype 9V98.5 (96.8 to 99.4)98.9 (97.5 to 99.7)98.2 (96.5 to 99.2)
Serotype 1498.9 (97.5 to 99.6)99.4 (98.1 to 99.9)97.8 (96.0 to 98.9)
Serotype 18C96.9 (94.9 to 98.3)98.1 (96.4 to 99.1)98.7 (97.1 to 99.5)
Serotype 19A99.3 (98.1 to 99.9)100.0 (99.2 to 100.0)99.3 (98.1 to 99.9)
Serotype 19F91.2 (88.2 to 93.6)91.0 (88.0 to 93.4)90.7 (87.6 to 93.2)
Serotype 23F94.3 (91.8 to 96.3)95.8 (93.5 to 97.4)94.9 (92.5 to 96.8)
Serotype 898.6 (97.0 to 99.5)99.1 (97.7 to 99.8)99.1 (97.7 to 99.7)
Serotype 10A99.7 (98.6 to 100.0)99.0 (97.6 to 99.7)99.3 (97.9 to 99.8)
Serotype 11A99.2 (97.8 to 99.8)99.5 (98.2 to 99.9)99.5 (98.2 to 99.9)
Serotype 12F99.0 (97.6 to 99.7)99.3 (97.9 to 99.9)99.0 (97.5 to 99.7)
Serotype 15B99.0 (97.4 to 99.7)98.6 (97.0 to 99.5)99.3 (97.8 to 99.8)
Serotype 22F99.7 (98.5 to 100.0)99.2 (97.8 to 99.8)99.5 (98.1 to 99.9)
Serotype 33F99.0 (97.4 to 99.7)98.8 (97.1 to 99.6)98.5 (96.8 to 99.5)

Adverse events

Collected over Local reactions: within 10 days after vaccination (systematic assessment), Systemic events: within 7 days after vaccination (systematic assessment), Non serious AEs: up to 1 month after vaccination, SAEs: up to 6 months after vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pooled 20vPnC0/1,463 (0%)10/1,463 (0.7%)1,275/1,463 (87.1%)
13vPnC0/245 (0%)0/245 (0%)206/245 (84.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPooled 20vPnC13vPnC
Splenic cystBlood and lymphatic system disorders1/14630/245
GastritisGastrointestinal disorders1/14630/245
Gastrooesophageal reflux diseaseGastrointestinal disorders1/14630/245
Hiatus herniaGastrointestinal disorders1/14630/245
Abdominal abscessInfections and infestations1/14630/245
OsteomyelitisInfections and infestations1/14630/245
Pneumonia mycoplasmalInfections and infestations1/14630/245
Staphylococcal bacteraemiaInfections and infestations1/14630/245
Procedural pneumothoraxInjury, poisoning and procedural complications1/14630/245
Subcutaneous haematomaInjury, poisoning and procedural complications1/14630/245
Most frequent other events
Most frequent other events
EventPooled 20vPnC13vPnC
Injection site pain (PAIN)General disorders1146/1463184/245
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders904/1463147/245
FatigueGeneral disorders693/1463106/245
HeadacheNervous system disorders527/146392/245
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders245/146334/245
Injection site swelling (SWELLING)General disorders124/146321/245
Injection site erythema (REDNESS)General disorders102/146315/245
Pyrexia (FEVER)General disorders18/14632/245

Baseline characteristics

Safety population included all participants who received 1 dose of any 20vPnC lot or 13vPnC and had safety follow-up after the vaccination.

Age, Continuous
Age, Continuous(years)20vPnC Lot 120vPnC Lot 220vPnC Lot 313vPnCTotal
Mean35.6 ± 9.1735.7 ± 9.0334.9 ± 9.0535.0 ± 8.7035.3 ± 9.03
Sex: Female, Male
Sex: Female, Male(Participants)20vPnC Lot 120vPnC Lot 220vPnC Lot 313vPnCTotal
Female3313163241441115
Male157173162101593
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20vPnC Lot 120vPnC Lot 220vPnC Lot 313vPnCTotal
Hispanic or Latino48585629191
Not Hispanic or Latino4344274272151503
Unknown or Not Reported643114
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20vPnC Lot 120vPnC Lot 220vPnC Lot 313vPnCTotal
American Indian or Alaska Native595423
Asian1317171259
Native Hawaiian or Other Pacific Islander21126
Black or African American87889744316
White3673513501731241
More than one race61313537
Unknown or Not Reported8103526
08

Study locations

21 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Kaiser Permanente Sacramento
    Sacramento, California 95815, United States
  • Kaiser Permanente South Sacramento
    Sacramento, California 95823, United States
  • Kaiser Permanente San Jose
    San Jose, California 95119, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Accel Research Sites - Clinical Research Unit
    DeLand, Florida 32720, United States
  • Research Centers of America, LLC
    Hollywood, Florida 33024, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/Adult Research
    Bardstown, Kentucky 40004, United States
  • Meridian Clinical Research, LLC
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Meridian Clinical Research, LLC
    Dakota Dunes, South Dakota 57049, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • J. Lewis Research, Inc. /Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. /Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
09

References and documents

Publications

  • Sabharwal C, Sundaraiyer V, Peng Y, Moyer L, Belanger TJ, Gessner BD, Jodar L, Jansen KU, Gruber WC, Scott DA, Watson W. Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease. Hum Vaccin Immunother. 2022 Nov 30;18(6):2126253. doi: 10.1080/21645515.2022.2126253. Epub 2022 Nov 11. PubMed 36368038 ↗
  • Klein NP, Peyrani P, Yacisin K, Caldwell N, Xu X, Scully IL, Scott DA, Jansen KU, Gruber WC, Watson W. A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. Vaccine. 2021 Sep 7;39(38):5428-5435. doi: 10.1016/j.vaccine.2021.07.004. Epub 2021 Jul 24. PubMed 34315611 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Oct 2019, 7 months.

Results were first posted in Nov 2020, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 7 months is below that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2019
First posted
Feb 4, 2019
StartActual
Feb 14, 2019
Primary completionActual
Oct 9, 2019
CompletionActual
Oct 9, 2019
Results first posted
Nov 4, 2020
Last update
Nov 23, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 23, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03828617
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 4, 2019
Start date
Feb 14, 2019
Primary completion
Oct 9, 2019
Completion
Oct 9, 2019
Results posted
Nov 4, 2020
Last update
Nov 23, 2020

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion